Profound Medical Files to Sell 921,428 Common Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Profound Medical files to sell 921,428 common shares for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PROF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PROF
Wall Street analysts forecast PROF stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.900
Low
11.00
Averages
11.67
High
12.00
Current: 6.900
Low
11.00
Averages
11.67
High
12.00
About PROF
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Telix Partners with Leaders in Ablative Technologies for Prostate Cancer
- Partnership Formation: Telix has entered into letters of intent with EDAP TMS and Profound Medical to develop advanced minimally invasive and image-guided ablative technologies for prostate cancer treatment, reflecting Telix's commitment to integrating molecular imaging into clinical practices.
- Technology Application Exploration: The collaboration will explore the integration of Telix's PSMA-PET imaging agents with robotic high-intensity focused ultrasound (HIFU) and other treatment methods, aiming to optimize treatment efficacy while minimizing side effects, thereby enhancing patient experience.
- Clinical Evidence Generation: Telix and its partners will work together to generate clinical evidence supporting best practices for prostate whole-gland, partial-gland, and focal ablation workflows, promoting the adoption of PSMA-PET imaging and enhancing personalized care.
- Precision Medicine Strategy: The CEO of Telix emphasized that as disruptive technologies continue to evolve, PSMA-PET imaging will play a crucial role in minimally invasive and image-guided treatments, driving collaborations with industry leaders to achieve personalized patient care.
See More
Telix Partners with Companies to Develop Advanced Prostate Cancer Treatments
- Partnership Formation: Telix has signed letters of intent with EDAP TMS and Profound Medical to develop advanced minimally invasive and image-guided technologies for prostate cancer treatment, marking a strategic expansion in the prostate cancer treatment landscape.
- Technology Integration: The collaboration will explore the integration of Telix's PSMA-PET imaging agents with high-intensity focused ultrasound (HIFU) and other treatment modalities, aiming to optimize treatment efficacy while minimizing side effects, thereby enhancing patient experience.
- Clinical Evidence Generation: The partnership will focus on generating clinical evidence to support the establishment of best practices, which is expected to accelerate the adoption of PSMA-PET imaging technology in prostate cancer treatment and promote the development of personalized medicine.
- Market Leadership: Telix's CEO emphasized that as minimally invasive technologies continue to evolve, the importance of PSMA-PET imaging in clinical decision-making is increasingly significant, and this collaboration will further solidify Telix's leadership position in the prostate cancer treatment market.
See More
Profound Medical Reports Q1 2026 Earnings with Strong Revenue Growth and Strategic Outlook
- Significant Revenue Growth: Profound Medical reported Q1 2026 revenue of $5.3 million, a 104% increase year-over-year, including $2.5 million from recurring revenue and $2.9 million from one-time capital equipment sales, indicating strong market performance and heightened product demand.
- High Gross Margin: The gross margin for Q1 stood at 72%, despite total operating expenses of $11.8 million, demonstrating the company's ability to maintain high profitability while controlling costs, thereby enhancing the sustainability of future growth.
- Clear Market Positioning: CEO Dr. Menawat emphasized TULSA's potential as a mainstream treatment modality, with 91% of patients treated involving whole gland or over 50% ablations, showcasing the company's competitive edge and technological leadership in the market.
- Optimistic Future Outlook: The company projects total revenue of approximately $25 million for 2026, with gross margins expected to remain above 70%, reflecting management's bullish stance on business prospects and commitment to achieving profitability through disciplined execution and market expansion.
See More
Bidding War Intensifies in AI Diagnostics Market
- Market Growth Potential: The global AI in medical imaging market is projected to reach $2.20 billion by 2026, with a 34.8% annual growth rate, indicating a rapid influx of capital into AI platforms that possess regulatory clearance and clinical data, reflecting strong demand for AI technologies in healthcare.
- Hospital Investment Trends: A recent C-suite survey reveals that 57% of hospitals now prioritize AI clinical solutions as their top technology focus for 2026 to 2027, a significant increase from just 19% in 2023, highlighting the growing importance of AI in medical institutions.
- Innovation Recognition: VentriPoint Diagnostics received a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform VMS+™ 4.0, marking a significant achievement in clinical application and reinforcing its competitive position among small-cap medtech companies.
- International Collaboration Expansion: VentriPoint's collaboration with the Health Division of the Montecristo Group aims to roll out VMS+™ across Costa Rica's public and private hospital networks, showcasing its potential for market expansion in Latin America, while also partnering with First Light Health to provide cardiac diagnostics to Indigenous and remote communities in Canada.
See More
Bidding War Intensifies for AI Diagnostics Market
- Market Growth Potential: The global AI in medical imaging market is projected to reach $2.20 billion by 2026, with a 34.8% annual growth rate, indicating a rapid influx of capital into AI platforms that possess regulatory clearance and clinical data, intensifying industry competition.
- Hospital Investment Trends: A recent C-suite survey reveals that 57% of hospitals now prioritize AI clinical solutions as their top technology focus for 2026 to 2027, a significant increase from just 19% in 2023, reflecting a heightened emphasis on AI technology in healthcare institutions.
- Recognition of Technological Innovation: VentriPoint Diagnostics received a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform VMS+™ 4.0, underscoring the effectiveness of its technology in clinical applications and further solidifying its competitive position in the medical imaging sector.
- International Collaboration Expansion: VentriPoint's partnerships with the Montecristo Group and First Light Health aim to promote cardiac diagnostics through its VMS+™ platform in Costa Rica and remote communities in Canada, demonstrating its potential for global market expansion and commitment to social responsibility.
See More
Profound Medical Corp to Announce Q1 2026 Financial Results
- Earnings Announcement Schedule: Profound Medical Corp will release its Q1 2026 financial results after market close on May 7, 2026, and will host a conference call at 4:30 p.m. ET to review financial performance and business developments, providing crucial guidance for investors.
- Technology Innovation Overview: Profound focuses on developing AI-powered, MRI-guided incision-free therapies, with its TULSA-PRO® platform enabling precise prostate treatments that support personalized strategies, significantly reducing side effects typically associated with surgery or radiation, thereby enhancing patient experience.
- Sonalleve® Product Introduction: The company also commercializes Sonalleve®, an MRI-guided non-surgical treatment option for bone metastases pain and common gynecological conditions, offering incision-free, bloodless procedures that shorten recovery time and may help preserve fertility.
- Global Market Approval Status: Profound's technologies have received approvals in major markets, with TULSA-PRO cleared in the U.S., Europe, and Canada, while Sonalleve is approved in the U.S., Europe, and China, indicating strong potential for global business expansion.
See More
Telix Partners with Leaders in Ablative Technologies for Prostate Cancer
- Partnership Formation: Telix has entered into letters of intent with EDAP TMS and Profound Medical to develop advanced minimally invasive and image-guided ablative technologies for prostate cancer treatment, reflecting Telix's commitment to integrating molecular imaging into clinical practices.
- Technology Application Exploration: The collaboration will explore the integration of Telix's PSMA-PET imaging agents with robotic high-intensity focused ultrasound (HIFU) and other treatment methods, aiming to optimize treatment efficacy while minimizing side effects, thereby enhancing patient experience.
- Clinical Evidence Generation: Telix and its partners will work together to generate clinical evidence supporting best practices for prostate whole-gland, partial-gland, and focal ablation workflows, promoting the adoption of PSMA-PET imaging and enhancing personalized care.
- Precision Medicine Strategy: The CEO of Telix emphasized that as disruptive technologies continue to evolve, PSMA-PET imaging will play a crucial role in minimally invasive and image-guided treatments, driving collaborations with industry leaders to achieve personalized patient care.
See More
Telix Partners with Companies to Develop Advanced Prostate Cancer Treatments
- Partnership Formation: Telix has signed letters of intent with EDAP TMS and Profound Medical to develop advanced minimally invasive and image-guided technologies for prostate cancer treatment, marking a strategic expansion in the prostate cancer treatment landscape.
- Technology Integration: The collaboration will explore the integration of Telix's PSMA-PET imaging agents with high-intensity focused ultrasound (HIFU) and other treatment modalities, aiming to optimize treatment efficacy while minimizing side effects, thereby enhancing patient experience.
- Clinical Evidence Generation: The partnership will focus on generating clinical evidence to support the establishment of best practices, which is expected to accelerate the adoption of PSMA-PET imaging technology in prostate cancer treatment and promote the development of personalized medicine.
- Market Leadership: Telix's CEO emphasized that as minimally invasive technologies continue to evolve, the importance of PSMA-PET imaging in clinical decision-making is increasingly significant, and this collaboration will further solidify Telix's leadership position in the prostate cancer treatment market.
See More
Profound Medical Reports Q1 2026 Earnings with Strong Revenue Growth and Strategic Outlook
- Significant Revenue Growth: Profound Medical reported Q1 2026 revenue of $5.3 million, a 104% increase year-over-year, including $2.5 million from recurring revenue and $2.9 million from one-time capital equipment sales, indicating strong market performance and heightened product demand.
- High Gross Margin: The gross margin for Q1 stood at 72%, despite total operating expenses of $11.8 million, demonstrating the company's ability to maintain high profitability while controlling costs, thereby enhancing the sustainability of future growth.
- Clear Market Positioning: CEO Dr. Menawat emphasized TULSA's potential as a mainstream treatment modality, with 91% of patients treated involving whole gland or over 50% ablations, showcasing the company's competitive edge and technological leadership in the market.
- Optimistic Future Outlook: The company projects total revenue of approximately $25 million for 2026, with gross margins expected to remain above 70%, reflecting management's bullish stance on business prospects and commitment to achieving profitability through disciplined execution and market expansion.
See More
Bidding War Intensifies in AI Diagnostics Market
- Market Growth Potential: The global AI in medical imaging market is projected to reach $2.20 billion by 2026, with a 34.8% annual growth rate, indicating a rapid influx of capital into AI platforms that possess regulatory clearance and clinical data, reflecting strong demand for AI technologies in healthcare.
- Hospital Investment Trends: A recent C-suite survey reveals that 57% of hospitals now prioritize AI clinical solutions as their top technology focus for 2026 to 2027, a significant increase from just 19% in 2023, highlighting the growing importance of AI in medical institutions.
- Innovation Recognition: VentriPoint Diagnostics received a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform VMS+™ 4.0, marking a significant achievement in clinical application and reinforcing its competitive position among small-cap medtech companies.
- International Collaboration Expansion: VentriPoint's collaboration with the Health Division of the Montecristo Group aims to roll out VMS+™ across Costa Rica's public and private hospital networks, showcasing its potential for market expansion in Latin America, while also partnering with First Light Health to provide cardiac diagnostics to Indigenous and remote communities in Canada.
See More
Bidding War Intensifies for AI Diagnostics Market
- Market Growth Potential: The global AI in medical imaging market is projected to reach $2.20 billion by 2026, with a 34.8% annual growth rate, indicating a rapid influx of capital into AI platforms that possess regulatory clearance and clinical data, intensifying industry competition.
- Hospital Investment Trends: A recent C-suite survey reveals that 57% of hospitals now prioritize AI clinical solutions as their top technology focus for 2026 to 2027, a significant increase from just 19% in 2023, reflecting a heightened emphasis on AI technology in healthcare institutions.
- Recognition of Technological Innovation: VentriPoint Diagnostics received a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform VMS+™ 4.0, underscoring the effectiveness of its technology in clinical applications and further solidifying its competitive position in the medical imaging sector.
- International Collaboration Expansion: VentriPoint's partnerships with the Montecristo Group and First Light Health aim to promote cardiac diagnostics through its VMS+™ platform in Costa Rica and remote communities in Canada, demonstrating its potential for global market expansion and commitment to social responsibility.
See More
Profound Medical Corp to Announce Q1 2026 Financial Results
- Earnings Announcement Schedule: Profound Medical Corp will release its Q1 2026 financial results after market close on May 7, 2026, and will host a conference call at 4:30 p.m. ET to review financial performance and business developments, providing crucial guidance for investors.
- Technology Innovation Overview: Profound focuses on developing AI-powered, MRI-guided incision-free therapies, with its TULSA-PRO® platform enabling precise prostate treatments that support personalized strategies, significantly reducing side effects typically associated with surgery or radiation, thereby enhancing patient experience.
- Sonalleve® Product Introduction: The company also commercializes Sonalleve®, an MRI-guided non-surgical treatment option for bone metastases pain and common gynecological conditions, offering incision-free, bloodless procedures that shorten recovery time and may help preserve fertility.
- Global Market Approval Status: Profound's technologies have received approvals in major markets, with TULSA-PRO cleared in the U.S., Europe, and Canada, while Sonalleve is approved in the U.S., Europe, and China, indicating strong potential for global business expansion.
See More
